p21Waf1/Cip1 dysfunction in neuroblastoma: A novel mechanism of attenuating G0-G1 cell cycle arrest

Cancer Research

Volumn 63, Issue 13, 2003, Pages 3840-3844

  McKenzie, Pamela P ^a   Danks, Mary K ^a   Kriwacki, Richard W ^a   Harris, Linda C ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR; PROTEIN P21; PROTEIN P53; RECOMBINANT PROTEIN; CDK2 PROTEIN, HUMAN; CDK4 PROTEIN, HUMAN; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLINE; ONCOPROTEIN; PROTEIN SERINE THREONINE KINASE;

ARTICLE; CANCER THERAPY; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CONTROLLED STUDY; DNA DAMAGE; ENZYME ACTIVITY; HUMAN; HUMAN CELL; NEUROBLASTOMA; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN EXPRESSION; CELL CYCLE; CHILD; GENE VECTOR; GENETIC TRANSFECTION; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY;

CDC2-CDC28 KINASES; CELL CYCLE; CHILD; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASES; CYCLINS; G0 PHASE; G1 PHASE; GENETIC VECTORS; HUMANS; NEUROBLASTOMA; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; RECOMBINANT PROTEINS; TRANSFECTION;

EID: 0038417604     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Matthay, K. K. Neuroblastoma: a clinical challenge and biological puzzle. CA Cancer J. Clin., 45: 179-192, 1995.
2. Vogan, K., Bernstein, M., Leclerc, J. M., Brisson, L., Brodeur, G. M., Pelletier, J., and Gros, P. Absence of p53 mutations in primary neuroblastomas. Cancer Res., 53: 5269-5273, 1993.
3. Frappez, D., Michon, J., Coze, C., Berger, C., Plouvier, E., Lasset, C., Bernard, J. L., Stephan, J. L., Bouffet, E., Buclon, M., Combaret, V., Fourquet, A., Philip, T., and Zucker, J. M. LCME3 treatment strategy: results in 99 consecutively diagnosed stage 4 neuroblastomas in children older than 1 year at diagnosis. J. Clin. Oncol., 18: 468-476, 2000.
4. LaBaer, J., Garrett, M. D., Stevenson, L. F., Slingerland, J. M., Sandhu. C., Chou, H. S., Fattaey, A., and Harlow, E. New functional activities for the p21 family of CDK inhibitors. Genes Dev., 11: 847-862, 1997.
5. 1-phase progression. Genes Dev., 13: 1501-1512, 1999.
6. El-Deiry, W. S., Harper, J. W., O'Conner, P. M., Velculescu, V. E., Canman, C. E., Jackman, J., Pietenpol, J. A., Burrell, M., Hill, D. E., Wang, Y., Wiman, K. G., Mercer, W. E., Kastan, M. B., Kohn, K. W., Elledge, S. J., Kinzler, K. W., and Vogelstein, B. WAF1/CIP1 is induced upon p53-mediated growth arrest and apoptosis. Cancer Res., 54: 1169-1174, 1994.
7. 1 checkpoint after DNA damage. Mol. Cell. Biol., 16: 1126-1137, 1996.
8. Goldman, S. C., Chen, C-Y., Lansing, T. J., Gilmer, T. M., and Kastan, M. B. The p53 signal transduction pathway is intact in human neuroblastoma despite cytoplasmic localization. Am. J. Pathol., 148: 1381-1385, 1996.
9. 1 checkpoint function is attenuated. Clin. Cancer Res., 5: 4199-4207, 1999.
10. 1 arrest despite WAFI induction in MYCN-amplified cells. Am. J. Pathol., 158: 2067-2077, 2001.
11. Waldman, T., Zhang, Y., Dillehay, L., Kinzler, K., Vogelstein, B., and Williams, J. Cell-cycle arrest versus cell death in cancer chemotherapy. Nat. Med., 3: 1034-1036, 1997.
12. Thompson, J., Zamboni, W. C., Cheshire, P. J., Lutz, L., Luo, X., Li, Y. J. A., H., and Houghton, P. J. Efficacy of systemic administration of irinotecan against neuroblastoma xenografts. Clin. Cancer Res., 3: 423-431, 1997.
13. McPake, C. R., Tillman, D. M., Poquette, C. A., George, E. O., Houghton, J. A., and Harris, L. C. Bax is an important determinant of chemosensitivity in pediatric tumor cell lines independent of Bcl-2 expression and p53 status. Oncol. Res., 10: 235-244, 1998.
14. Taylor, A. C., Shu, L., Danks, M. K., Poquette, C. A., Shetty, S., Thayer, M. J., Houghton, P. J., and Harris, L. C. p53 mutation and MDM2 amplification frequency in pediatric rhabdomyosarcoma tumors and cell lines. Med. Pediatr. Oncol., 35: 96-103, 2000.
15. Pirollo, K. F., Hao, Z., Rait, A., Jang, Y-J., Fee Jr., W. E., Ryan, P., Chiang, Y., and Chang, E. H. p53 mediated sensitization of squamous cell carcinoma of the head and neck to radiotherapy. Oncogene, 14: 1735-1746, 1997.
16. Gitig, D. M., and Koff, A. Cdk pathway: cyclin-dependent kinases and cyclin-dependent kinase inhibitors. Methods Mol. Biol., 142: 109-123, 2000.
17. 1 cyclins and cyclin-dependent kinase-2 activity during terminal differentiation of cultured human trophoblast. Biol. Reprod., 58: 1283-1289, 1998.
18. Foster, J. S., Henley, D. C., Bukovsky, A., Seth, P., and Wimalasena, J. Multifaceted regulation of cell cycle progression by Estrogen: Regulation of cdk inhibitors and Cdc25 independent of cyclin D1-cdk4 function. Mol. Cell. Biol., 21: 794-810, 2001.
19. Kriwacki, R. W., Hengst, L., Tennant, L., Reed, S. I., and Wright, P. E. Structural studies of p21Waf1/Cip1/Sdi1 in the free and Cdk2-bound state: conformational disorder mediates binding diversity. Proc. Natl. Acad. Sci. USA. 93: 11504-11509, 1996.
20. Guy, M., Moorghen, M., Bond, J. A., Collard, T. J., Paraskeva, C., and Williams, A. C. Transcriptional down-regulation of the retinoblastoma protein is associated with differentiation and apoptosis in human colorectal epithelial cells. Br. J. Cancer, 84: 520-528, 2001.
21. Fusaro, G., Wang, S., and Chellappan, S. Differential regulation of Rb family proteins and prohibitin during camptothecin-induced apoptosis. Oncogene, 21: 4539-4548, 2002.
22. Chellappan, S. P., Hiebert, S., Mudryj, M., Horowitz, J. M., and Nevins, J. R. The E2F transcription factor is a cellular target for the RB protein. Cell, 65: 1053-1061, 1991.
23. Russo, A. A., Jeffrey, P. D., Patten, A. K., Massague, J., and Pavletich, N. P. Crystal structure of the p27Kip1 cyclin-dependent-kinase inhibitor bound to the cyclin A-Cdk2 complex. Nature (Lond.), 382: 325-331, 1996.
24. 1 arrest after γ-irradiation. Proc. Natl. Acad. Sci. USA, 96: 1002-1007, 1999.
25. Wang, S., Nath, N., Minden, A., and Chellappan, S. Regulation of Rb and E2F by signal transduction cascades: divergent effects of JNK1 and p38 kinases. EMBO J., 18: 1559-1570, 1999.
26. McPake, C. R., Shetty, S., Kitchingman, G. R., and Harris, L. C. Wild-type p53 induction mediated by replication deficient adenoviral vectors. Cancer Res., 59: 4247-4251, 1999.
27. El Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. P., Parsons, R., Trent, J. M., Liu, D., Merrer, W. E., Kinzler, K. W., and Vogelstein, B. WAF1, a potential mediator of p53 tumor suppression. Cell, 75: 817-825, 1993.
28. 1 cyclin-dependent kinases. Cell, 75: 805-816, 1993.
29. Xiong, Y., Hannon, G. J., Zhang, H., Casso. D., Kobayashi, R., and Beach, D. p21 is a universal inhibitor of cyclin kinases. Nature (Lond.), 366: 701-704, 1993.
30. 1 cyclin-dependent kinase complexes in vivo. Mol. Cell. Biol., 21: 4773-4784, 2001.
31. 1. Cell, 98: 859-869, 1999.